Rosabel Alinaya Net Worth

The estimated Net Worth of Rosabel Realica Alinaya is at least $711 mil dollars as of 30 June 2017. Ms. Alinaya owns over 2,000 units of Mannkind Corp stock worth over $184,458 and over the last 9 years she sold MNKD stock worth over $6,672. In addition, she makes $519,586 as Vice President of Investor Relations, Interim Corporate Controller y Treasurer at Mannkind Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Alinaya MNKD stock SEC Form 4 insiders trading

Rosabel has made over 3 trades of the Mannkind Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently she bought 2,000 units of MNKD stock worth $2,460 on 30 June 2017.

The largest trade she's ever made was buying 9,043 units of Mannkind Corp stock on 3 January 2017 worth over $4,883. On average, Rosabel trades about 1,156 units every 24 days since 2016. As of 30 June 2017 she still owns at least 30,091 units of Mannkind Corp stock.

You can see the complete history of Ms. Alinaya stock trades at the bottom of the page.

Rosabel Alinaya biography

Rosabel Realica Alinaya CPA serves as Vice President of Investor Relations, Interim Corporate Controller, Treasurer of the Company. Ms. Alinaya also served as Principal Accounting Officer from January 2016 to July 2017 with responsibility for finance, accounting, tax, treasury, investor relations and risk management. Previously, she was our Vice President, Finance since March 2011 after serving as our Corporate Controller since June 2003. Ms. Alinaya began her career at Deloitte & Touche LLP, graduating from California State University, Northridge and is a Certified Public Accountant. She is also a member of the American Institute of Certified Public Accountants and a member of the California Society of Certified Public Accountants.

What is the salary of Rosabel Alinaya?

As the Vice President of Investor Relations, Interim Corporate Controller y Treasurer of Mannkind Corp, the total compensation of Rosabel Alinaya at Mannkind Corp is $519,586. There are 11 executives at Mannkind Corp getting paid more, with Michael Castagna having the highest compensation of $1,551,760.

How old is Rosabel Alinaya?

Rosabel Alinaya is 59, she's been the Vice President of Investor Relations, Interim Corporate Controller y Treasurer of Mannkind Corp since 2019. There are 7 older and 15 younger executives at Mannkind Corp. The oldest executive at Mannkind Corp is Kent Kresa, 82, who is the Independent Chairman of the Board.

What's Rosabel Alinaya's mailing address?

Rosabel's mailing address filed with the SEC is 30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE, CA, 91362.

Insiders trading at Mannkind Corp

Over the last 20 years, insiders at Mannkind Corp have traded over $14,187,027 worth of Mannkind Corp stock and bought 107,212,962 units worth $2,707,661,837 . The most active insiders traders include Alfred E Mann, Juergen Martens y David Thomson. On average, Mannkind Corp executives and independent directors trade stock every 27 days with the average trade being worth of $3,220,647. The most recent stock trade was executed by Stuart A Tross on 3 September 2024, trading 25,000 units of MNKD stock currently worth $156,500.

What does Mannkind Corp do?

mannkind corporation (nasdaq: mnkd) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. in addition, mannkind is applying our novel technologies and services to support partner development efforts.

Complete history of Ms. Alinaya stock trades at Mannkind Corp

Mannkind Corp executives and stock owners

Mannkind Corp executives and other stock owners filed with the SEC include:

• Michael Castagna,
  Chief Executive Officer, Director
• Dr. Michael E. Castagna Pharm.D.,
  CEO & Director
• Stuart Tross,
  Chief People and Workplace Officer
• David Thomson,
  Executive Vice President, General Counsel, Secretary
• Dr. Michael E. Castagna,
  CEO & Director
• Steven Binder,
  Chief Financial Officer
• Dr. David B. Thomson,
  Exec. VP, Gen. Counsel & Sec.
• Joseph Kocinsky,
  Chief Technology Officer
• Steven B. Binder,
  Chief Financial Officer
• Joseph Kocinsky M.B.A., M.S.,
  Chief Technology Officer
• Dr. Stuart A. Tross,
  Chief People & Workplace Officer
• Rosabel Alinaya,
  Vice President of Investor Relations, Interim Corporate Controller, Treasurer
• Christine Mundkur,
  Independent Director
• Kent Kresa,
  Independent Chairman of the Board
• Ronald Consiglio,
  Independent Director
• Michael Friedman,
  Independent Director
• James Shannon,
  Independent Director
• Kevin Kaiserman,
  Vice President - Medical Affairs and Safety
• Jennifer Grancio,
  Independent Director
• Anthony Hooper,
  Independent Director
• Alejandro Galindo M.B.A., M.S.,
  Chief Commercial Officer
• James Patrick McCauley Jr., J.D., M.B.A.,
  Chief Commercial Officer
• John F. Bedard,
  Sr. VP of Worldwide Regulatory Affairs
• Rosabel Realica Alinaya,
  VP of Investor Relations & Treasury
• Thomas Hofmann M.D., Ph.D.,
  Chief Scientific Officer
• Matthew J Pfeffer,
  Corporate VP and CFO
• Henry L Nordhoff,
  Director
• David Mac Callum,
  Director
• Raymond W. Urbanski,
  Corp VP, CMO
• David M Kendall,
  Chief Medical Officer
• Elizabeth Garrett Ingram,
  Chief Marketing Officer
• Courtney Barton,
  Chief Compl & Privacy Officer
• Patrick Mc Cauley,
  Chief Commercial Officer
• John R. Riesenberger,
  VP & Chief Commercial Officer
• Richard L Anderson,
  VP & CFO
• Heather Hay Murren,
  Director
• Kathleen Connell,
  Director
• Llew Keltner,
  Director
• Dan Burns,
  VP & President, MKBP
• W Wendell Cheatham,
  VP, Medical & Reg Affairs
• Juergen Martens,
  Corporate VP
• Hakan Edstrom,
  President & COO
• Alfred E Mann,
  Chairman & CEO
• Diane Palumbo,
  Vice President, Human Resource
• Abraham E Cohen,
  Director
• Peter C Richardson,
  Chief Scientific Officer
• Lauren M Sabella,
  EVP Chief Operating Officer
• Alejandro Galindo,
  EVP Endocrine Business Unit
• Burkhard Blank,
  EVP Chief Medical Officer
• Sanjay R Singh,
  EVP Technical Operations
• Christopher B Prentiss,
  Chief Financial Officer
• Sabrina Kay,